Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis

Journal of Infection

Volumn 67, Issue 1, 2013, Pages 72-78

  Singh, Nina ^a   Suarez, Jose F ^b   Avery, Robin ^c   Lass Flörl, Cornelia ^d   Geltner, Christian ^d   Pasqualotto, Alessandro C ^e   Marshall Lyon, G ^f   Barron, Michelle ^g   Husain, Shahid ^h   Wagener, Marilyn M ^a   Montoya, Jose G ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b STANFORD UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aspergillosis; Lung nodules; Lung transplant; Transplant

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY FAILURE; LUNG ASPERGILLOSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; RISK FACTOR; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

EID: 84878367679     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.03.013     Document Type: Article

References (27)

1. Arthurs S.K., Eid A.J., Deziel P.J., Marshall W.F., Cassivi S.D., Walker R.C., et al. The impact of invasive fungal diseases on survival after lung transplantation. Clinical Transplantation 2010, 24:341-348.
2. Iversen M., Burton C.M., Vand S., Skovfoged L., Carlsen J., Milman N., et al. Aspergillus infection in lung transplant patients: incidence and prognosis. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2007, 26:879-886.
3. Sole A., Morant P., Salavert M., Peman J., Morales P. Aspergillus in lung transplant recipients: risk factors and outcome. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2005, 11:359-365. the Valencia Lung Transplant Group.
4. Avery R.K. Antifungal prophylaxis in lung transplantation. Seminars in Respiratory and Critical Care Medicine 2011, 32:717-726.
5. Logan P.M., Muller N.L. CT manifestations of pulmonary aspergillosis. Critical Reviews in Diagnostic Imaging 1996, 37:1-37.
6. Park S.Y., Lim C., Lee S.O., Choi S.H., Kim Y.S., Woo J.H., et al. Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value. The Journal of Infection 2011, 63:447-456.
7. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2007, 44:373-379.
8. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2008, 46:1813-1821.
9. Humar A., Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006, 6:262-274.
10. Austin J.H., Muller N.L., Friedman P.J., Hansell D.M., Naidich D.P., Remy-Jardin M., et al. Glossary of terms of CT of the lungs; recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996, 200:327-331.
11. Copp D.H., Godwin J.D., Kirby K.A., Limaye A.P. Clinical and radiologic factors associated with pulmonary nodule etiology in organ transplant recipients. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006, 6:2759-2764.
12. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. The New England Journal of Medicine 2002, 347:408-415.
13. Baddley J.W., Andes D.R., Marr K.A., Kontoyiannis D.P., Alexander B.D., Kauffman C.A., et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2010, 50:1559-1567.
14. Ramos E.R., Jiang Y., Hachem R., Kassis C., Kontoyiannis D.P., Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. The Oncologist 2011, 16:1049-1060.
15. Singh N., Paterson D.L. Aspergillus infections in transplant recipients. Clinical Microbiology Reviews 2005, 18:44-69.
16. Sherif R., Segal B.H. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Current Opinion in Pulmonary Medicine 2010, 16:242-250.
17. Casadevall A., Perfect J.A., Casaderall A. Tissue responses and special topics in immunity. Cryptococcus neoformans 1998, 271-324. ASM Press, Washington, DC.
18. Singh N., Alexander B.D., Lortholary O., Dromer F., Gupta K.L., John G.T., et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2008, 46:e12-e18.
19. Meyohas M.C., Roux P., Bollens D., Chouaid C., Rozenbaum W., Meynard J.L., et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1995, 21:628-633.
20. Loernic A.M., Bottone E.J., Finkel L.J., Teirstein A.S. Primary cryptococcal pneumonia mimicking Pneumocystis carinii pneumonia in patient with AIDS. The Mount Sinai Journal of Medicine, New York 1998, 55:181-186.
21. Miller W.T., Edelman J.M. Cryptococcal pulmonary infection in patients with AIDS: radiographic appearance. Radiology 1990, 175:725-728.
22. Cameron M.L., Bartlett J.A., Gallis H.A., Waskin H.A. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Reviews of Infectious Diseases 1991, 13:64-67.
23. Milito M.A., Kontoyiannis D.P., Lewis R.E., Liu P., Mawlawi O.R., Truong M.T., et al. Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. Medical Mycology: Official Publication of the International Society for Human and Animal Mycology 2010, 48:817-823.
24. Lamaris G.A., Ben-Ami R., Lewis R.E., Kontoyiannis D.P. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole invitro affect its virulence and the invivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. The Journal of Antimicrobial Chemotherapy 2008, 62:539-542.
25. Erasmus J.J., Gladish G.W., Broemeling L., Sabloff B.S., Truong M.T., Herbst R.S., et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2003, 21:2574-2582.
26. Horger M., Hebart H., Einsele H., Lengerke C., Claussen C.D., Vonthein R., et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome?. European Journal of Radiology 2005, 55:437-444.
27. Greene R.E., Mauskopf J., Roberts C.S., Zyczynski T., Schlamm H.T. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists 2007, 64:2561-2568.